Coenzyme Q10 Statin Myalgia Meta-analysis: What the Evidence Says

Quick Answer

Coenzyme Q10 Statin Myalgia Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This isoprenoid is essential for the endogenous synthesis of CoQ10.As CoQ10 is only supplied in small quantities with food and is predominantly synthesised endogenously,statin intake can lead to reduced CoQ10 levels. [Kovacic Svenja (2025); evidence level 1]
• In order to evaluate the potential bias on the individual study level and to summarise the results, the RoB2 online tool was used.Risk of bias assessment was conducted by SK and SH. [Kovacic Svenja (2025); evidence level 1]
• Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease. [Wu Xun (2026); evidence level 3]
• Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction. [Wu Xun (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For coenzyme q10 statin myalgia meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kovacic Svenja (2025). Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis. DOI: 10.1017/jns.2025.10043. PMCID: PMC12554813. PMID: 41158831. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12554813/
• Wu Xun (2026). Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives. DOI: 10.3389/fmolb.2025.1699492. PMCID: PMC12883399. PMID: 41669146. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12883399/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.